Immune Checkpoint Inhibitor-Related Myocarditis, Myopathy, and More: Unraveling the Tangled Science of Immune-Related Adverse Events.

Although numerically higher rates of in-hospital cardiovascular mortality or all-cause mortality in the irM/M overlap cohort did not reach statistical significance, it may be reasonable to describe this group as having had a more fulminant immune-related response, with statistically significant higher rates of concomitant grade 3/4 irAEs (16 [50.0%] vs 18 [26%]), steroid requirements (32 [100.0%] vs 55 [79.7%]), steroid refractoriness [21 [67.7%] vs 17 [29.3%]], additional immunosuppressant use (26 [81.2%] vs 19 [27.5%]) and BiPAP/endotracheal intubation use (9 [28.1%] vs 8 [11.6%]).

also in 111,027 other papers